glp-1 weight loss drug news today Amazon's New GLP‑1 Service Promises Less Expensive, Faster Access to Popular Weight‑Loss Drugs New GLP-1 alternative, eloralintide, leads

doi: 10.1177/1533317520953041 [DOI] [PMC free article] [PubMed] [Google Scholar] 235

Clinical evidence, encompassing trials, epidemiological investigations, and findings from animal toxicology and histological studies, has revealed potential associations between GLP-1RAs and the risk of neuroendocrine tumors and exocrine pancreatic dysplasia, with some evidence suggesting an increased risk of pancreatic cancer [6]

and global prevalence of type 2 diabetes and obesity, advancements in drug development, and expanding indications for weight loss and cardiovascular health

Therefore, patients must continuously use the drug if they want to maintain their weight

19 In regard to CKD, these clinical trials have also shown positive effects in the composite renal outcomes

35 The mechanisms underlying the effect of GLP-1 receptor agonists on OSA remain incompletely understood but are believed to be largely mediated through weight reduction.[45] OFF-LABEL AND INVESTIGATIONAL USES OF GLP-1RAS Investigational and off-label indications of GLP1-RAs are conditions that may have some evidence of benefit, but which currently lack FDA approval for a particular medication